Hong Kong – Caritas Medical Centre appeals to public for missing patient
Caritas Medical Centre appeals to public for missing patient
************************************************************
The following is issued on behalf of the Hospital Authority:
The spokesman for Caritas Medical Centre (CMC) made the following appeal today (June 30) regarding a patient leaving the Accident and Emergency Department (A&E) without prior notification:
A 24-year-old female patient with chronic disease was sent to the A&E by ambulance yesterday morning (June 29) at around 7am. The patient was found leaving the hospital without prior notification at around 8.45am. CMC is very concerned about the incident. Hospital security guards were mobilised to conduct local and hospital-wide search but in vain. Then, the hospital reported to the Police immediately.
The patient is about 1.5 meters tall, thin build with black medium-short hair. She wore a black T-shirt, black jeans and a green backpack.
The hospital appeals to the public to contact Cheung Sha Wan Police Station at 3661 1644 or call 999 if they know the whereabouts of the patient.
l CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients 6 years of age and older with seizure clusters/acute repetitive seizures. The Product can be administered at anytime and anywhere, and has the differentiated advantage of seizure rescue, with the characteristic of convenience and optimization through intranasal administration l The Product’s formulation incorporates a unique combination of Vitamin E-based solvents and Intravail® absorption enhancer, and the Product has high bioavailability, outstanding absorbability, tolerance and reliability l In 2023, CMS’s innovation development is stepping into a new cycle of harvesting, and the Product is CMS’s third innovative drug approved for marketing in China this year SHENZHEN, CHINA, June 12, 2023 – (ACN Newswire) – On June 12, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray (the “Product”) received approval from the National Medical Products Administration of China (NMPA). The Product is the first diazepam nasal spray in China, and it is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older. The Product is a proprietary formulation of diazepam administered through the nasal mucosa, and has high bioavailability, outstanding absorbability, tolerance and reliability. Product formulation incorporates a combination of Vitamin E-based solvents and Intravail® absorption enhancer. Intravail® transmucosal absorption enhancement technology enables the non-invasive delivery of a broad range of proteins, peptides and small-molecule drugs. The results of the Product’s US related clinical trial showed that 87% of seizure cluster episodes used a single dose of the Product over a 24-hour period. A post hoc analysis of these data showed the Product had a rapid onset of action with the median time from administration of the Product to seizure cessation of 4 minutes. Further analyses showed using the Product as intermittent rescue therapy significantly improves the quality of life of epileptic patients and may reflect a beneficial effect in increasing time between seizure clusters. In 2020, the Product was approved for marketing in the United States of America. The active pharmaceutical ingredient of the Product is Diazepam, belonging to the class of benzodiazepines, which are the first-choice drugs for the treatment of seizure clusters. However, there has been a lack of drugs for the treatment of seizure clusters in the China. The Product is the first drug approved in China for the treatment of seizure clusters. It can be administered intranasally at the appropriate time by patients or their caregivers under prescription from a doctor and guidance from medical staff. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients with seizure clusters. The Product can be administered anytime and anywhere, and has the differentiated advantage of seizure rescue, with the characteristic of convenience and optimization through intranasal administration. CMS has always focused on unmet clinical needs, and joined hands with global innovation forces to build a pharmaceutical innovation ecosystem in an open and collaborative setting, to continuously develop differentiated innovative products for patients. Starting from 2023, CMS’s innovation development is stepping into a new cycle of harvesting. Diazepam Nasal Spray is CMS’s third innovative drug approved for marketing in China this year, following the approval of Methotrexate Injection and Tildrakizumab Injection. CMS will steadily prepare for the commercialization of innovative products to benefit more patients in China as soon as possible. Seizure Clusters/Acute Repetitive Seizures According to the clinical diagnosis and treatment guidelines epilepsy volume (revision in 2023), seizure clusters/acute repetitive seizures are defined as ≥3 seizures/24h for adults, ≥3 seizures/12h for children, ≤8h between each seizures, and the consciousness returning to normal level between the two seizures. Seizure clusters are common in certain epilepsy syndromes, menstrual seizures, and drug-refractory epilepsy. If not treated in time, some will develop into status epilepticus, endangering the lives of patients. According to estimation, there are about 6.4 million active epilepsy patients in China, and about 0.3 million new cases reported each year. However, due to a lack of proper awareness towards epilepsy and limited medical resources, the current treatment gap for patients with active epilepsy in China is 49.8%, based on which it is estimated that about 3 million patients with active epilepsy in China have not received appropriate treatment. At present, there is still a lack of epidemiological research on seizure clusters in China. According to overseas studies, the rate of outpatient incidence of seizure clusters is about 15% and therefore it is estimated that nearly 500,000 patients with active epilepsy receiving regular treatment still have seizure clusters. For further detailed information regarding Diazepam Nasal Spray, please see the following link for “Voluntary and Business Update Announcement: New Drug Application of Diazepam Nasal Spray Approved in China” issued by CMS on June 12, 2023: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0612/2023061200453.pdf About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs. In 2022, the Group recorded a turnover of RMB9,150 million; in the case that all medicines were directly sold by the Group, the turnover reached RMB10,498 million. Profit for the year reached RMB3,276 million. CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. On May 30, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. – CMS is pleased to announce the NDA of Tildrakizumab Injection under the brand name of ILUMETRI, a monoclonal antibody specifically targeting the p19 subunit of IL-23, has been approved in China. ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMETRI is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMETRI has patents on composition and formulation in China. The results of the extended study of its Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance. ILUMETRI only needs to be administered 4 times a year during maintenance treatment period, which may bring higher patient compliance. Psoriasis is an autoimmune disease with complex causes, where IL-23 is regarded as one of the important driving factors of the pathogenesis of psoriasis. The incidence of psoriasis in China is about 0.47%, with the number of patients exceeding 7 million, of which more than 30% have developed into moderate-to-severe disease. ILUMETRI will provide moderate-to-severe plaque psoriasis patients with a safe and effective treatment option. It took only 14 months from obtaining the approval for the drug clinical trial to submitting the NDA for ILUMETRI in China, with the enrollment of 220 subjects completed in only 2.5 months (which included the Spring Festival), highlighting CMS’s highly efficient clinical development capabilities supported by its commercialization strength. ILUMETRI is CMS’s second innovative drug approved to be marketed in China in 2023, following the recent approval of Methotrexate Injection. CMS has invested in, and collaborated with, innovative companies globally over the last 5 years to jointly develop innovative products with academic value and differentiated advantages, in order to meet unmet clinical needs and enhance the accessibility of global innovative drugs for Chinese patients. Starting from 2023, CMS’s innovation development is stepping into the harvest period. ILUMETRI has been approved for marketing in the Hong Kong Special Administrative Region of China in April 2022. Tildrakizumab Injection has also been approved for marketing in the U.S., EU, Japan, UK, Switzerland, Canada, Australia and other countries/regions. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs. In 2022, the Group recorded a turnover of RMB9,150 million; in the case that all medicines were directly sold by the Group, the turnover reached RMB10,498 million. Profit for the year reached RMB3,276 million. CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group. Media Contact Q’Apel Medical Inc. was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 patients in the United States. The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. Importantly, Walrus enables the physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke. “The anticipation of Walrus in our international markets has been enormous, and we look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States,” said King Nelson, Q’Apel Medical’s CEO. “We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q’Apel Medical providing access to new markets,” commented Jodie Fam, Chief Marketing Officer & GM International. About Q’Apel Medical Q’Apel Medical designs highly innovative technologies for neurovascular interventions and unmet clinical needs. Q’Apel’s portfolio comprises three products, the Walrus Balloon Catheter System, the Wahoo Hybrid Access System and Armadillo Radial Access System. Before Walrus came along, balloon-based variable stiffness catheters brought all manner of technological constraints. Not anymore. By blending flow control, trackability, support, and access into one revolutionary solution, Walrus offers truly unmatched functionality. The Wahoo Hybrid Access System and Armadillo Radial Access System are dual-mode catheters and part of the SelectFlex(TM) Family of Neurovascular Catheters. These devices feature two distinct operational modes, allowing physicians to easily switch modes at any point during a clinical case and reducing the need for multiple catheters in challenging procedures.
For the last 100 years, Swedish Medical Center has been meeting the medical needs of Englewood and surrounding communities. As the community’s needs have changed over time, the hospital has grown and enhanced services to provide the highest level of care. Now, a Level 1 trauma center treating the region’s most complex medical cases, the hospital has turned its attention to expanding its emergency department (ED) space to streamline and improve care excellence. This project is part of a larger construction project in which the hospital built a new northwest tower near the corner of Girard Avenue and Logan Street in Englewood. The enhanced emergency department will be located adjacent to the new tower. This month, the hospital begins phase 1 of the expansion plan. During this phase, the ED will relocate its entrance and triage space temporarily until the department’s final construction is completed (expected for Sept. 2023). Phase 1 is not just a holding phase, however. It will actually allow improved access to the emergency department with 24/7 valet, a covered entrance and five valet lines that can be used during high volume. “We’ve heard from our patients about some of the amenities and resources they’d like to see in our space, and we have taken those to heart,” explains Elisha Nunley, vice president of emergency services. “In response, we have secured an Englewood police officer who will be stationed at the front door to greet guests and ensure the highest level of protection. We also have enhanced our privacy with new treatment rooms that allow our providers to begin patient’s care and answer questions in a private space.” Phase 2 will begin approximately a week after phase 1. This phase focuses on optimizing the permanent waiting room and triage area. At the completion of phase 2, the hospital will be able to offer patients a smoother experience with more privacy and dedicated treatment rooms. “Moving into this new space is really representative of what we stand for at Swedish. We have had a few difficult years in healthcare, and there are only a few places that are able to build right now,” Dr. Tsipis concludes. “At Swedish, we’re not stopping. We’re expanding. We’re innovating. We’re pushing the envelope to provide the absolute best care of patients. And that’s exactly what we are going to do.” To learn more about the project, and emergency services at Swedish Medical Center, visit the hospital’s Web site at SwedishHospital.com. About Swedish Medical Center As a national leader in neurosciences, Swedish serves as the hub of the Swedish Neuro Network. The hospital is the Rocky Mountain Region’s preeminent referral center for the most advanced stroke treatment and was the state’s first Joint Commission certified Comprehensive Stroke Center. Swedish also is home to Colorado’s first fully comprehensive robotics program with nine robots in dedicated robotics operating rooms; patients benefit from a high level of specialization with robotics-trained caregivers at every stage of treatment, as well as robotics-specific design in the program’s dedicated pre-op, ORs, PACU and inpatient spaces. As the region’s neurotrauma and orthopedic trauma provider and a level I trauma facility, more than 150 facilities regularly transfer highly complex cases to Swedish. The trauma program includes a burn and reconstructive center, which has been certified for adult burn care by the American Burn Association and recognized nationally for providing the highest quality of care to adult and pediatric burn and reconstructive patients. Swedish Medical Center is proud to be a part of the HCA Healthcare’s Continental Division, which was named the top health system in the state by IBM Watson Health and our system was named one of the top five large health systems in the country. This division includes our local system, HealthONE, which also received recognition as the top health system in the state by IBM Watson Health. Consistently among the Denver Business Journals’ list of top corporate philanthropists in the Denver-metro area, HealthONE contributed more than $889,000 through cash and in-kind donations last year alone, and also provided $677M in charity, uninsured and other uncompensated care along with nearly $200M in federal, state and local taxes. Swedish Medical Center Categories
China Medical System: The first ‘Diazepam Nasal Spray’ Approved for Marketing in China
Topic: Press release summaryChina Medical System: An Innovative Drug, ILUMETRI ‘Tildrakizumab Injection’ Approved for Marketing in China
– The extended study of ILUMETRI’s Phase III clinical trial in China, demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance.
– ILUMETRI only needs to be administered 4 times a year during maintenance treatment period, which may bring higher patient compliance.
– ILUMETRI will synergize with CMS Aesthetics’ marketed products, Hirudoid, Aethoxysklerol and pipeline products, to solidify comprehensive competitiveness of CMS in the dermatology field.
– This is CMS’s second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.
CMS Investor Relations
China Medical System Holdings Ltd.
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/Q’Apel Medical Inc. Granted CE Mark Under MDR for Their Walrus Balloon Guide Catheter
Swedish Medical Center Builds Innovative ED to Serve Region’s Most Complex Needs
Swedish Medical Center is located in the south metro Denver area where it has been a proud member of the community for more than 110 years. An acute care hospital with 408 licensed beds, annually Swedish cares for more than 200,000 patients with a team of approximately 2,000 dedicated employees, 300 volunteers and 1,400 physicians.
Richard Grissom
(303) 788-5944
SwedishHospital.com
Contact
Ads
